Having trouble viewing?
Click to downloadIf you are unable to download this pdf file, please try again in another browser.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Breast Cancer Patients Desire Early, Frequent Financial Screening
November 11th 2024Current financial screening procedures in the United States may need to change, according to recent research done by Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
The Takeaway From Study of Midlife MS Patients: Don't Stop Disease-Modifying Therapy
Published: November 11th 2024 | Updated: November 11th 2024People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.
Read More